Biopharma industry veteran Jackie Elbonne, Ph.D., is retiring at the end of the year, leaving Amgen’s top quality spot to her ...

Bayer’s pharmaceutical business may finally be entering a long-awaited growth cycle, but CEO Bill Anderson still can’t quite ...

In a major reshaping of the pharmaceutical contract manufacturing landscape, Lonza has struck a deal to acquire the CDMO ...

Pfizer's third-quarter performance bested Wall Street estimates thanks to an Eliquis beat and 37% growth from acquired products.

To Bill Sibold, “it’s hard to find a more attractive growth opportunity in biotech” than metabolic dysfunction-associated steatohepatitis (MASH). | To Madrigal CEO Bill Sibold, “it’s hard to find a ...

Karyopharm Therapeutics filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech, Ayrmid. Massachusetts-based Karyopharm’s financial woes came to a head in August, when ...

Sanofi has predicted that Dupixent will receive “the majority of the benefit” from the direct-to-consumer (DTC) marketing ca ...

In a pair of recently disclosed reports, the FDA outlined manufacturing concerns at separate facilities run by China's Hansoh ...

The direct-to-patient (DTP) market is full of providers making bold claims. But claims are not outcomes. | The DTP space is ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

In total, Fresenius aims to expand its biosimilar portfolio to as many as 66 molecules, targeting branded drugs with combined sales of more than 370 billion euros at list prices. The company’s nine ...

Dexcom has also tapped Chris Megino, who has built an online following sharing his journey with type 2 diabetes, and Chelsea ...